Which lipid measurement should we monitor? An analysis of the LIPID study

Objectives To evaluate the optimal lipid to measure in monitoring patients, we assessed three factors that influence the choice of monitoring tests: (1) clinical validity; (2) responsiveness to therapy changes and (3) the size of the long-term ‘signal-to-noise’ ratio. Design Longitudinal analyses of repeated lipid measurement over 5 years. Setting Subsidiary analysis of a Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study—a clinical trial in Australia, New Zealand and Finland. Participants 9014 patients aged 31–75 years with previous acute coronary syndromes. Interventions Patients were randomly assigned to 40 mg daily pravastatin or placebo. Primary and secondary outcome measures We used data on serial lipid measurements—at randomisation, 6 months and 12 months, and then annually to 5 years—of total cholesterol; low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and their ratios; triglycerides; and apolipoproteins A and B and their ratio and their ability to predict coronary events. Results All the lipid measures were statistically significantly associated with future coronary events, but the associations between each of the three ratio measures (total or LDL cholesterol to HDL cholesterol, and apolipoprotein B to apolipoprotein A1) and the time to a coronary event were better than those for any of the single lipid measures. The two cholesterol ratios also ranked highly for the long-term signal-to-noise ratios. However, LDL cholesterol and non-HDL cholesterol showed the most responsiveness to treatment change. Conclusions Lipid monitoring is increasingly common, but current guidelines vary. No single measure was best on all three criteria. Total cholesterol did not rank highly on any single criterion. However, measurements based on cholesterol subfractions—non-HDL cholesterol (total cholesterol minus HDL cholesterol) and the two ratios—appeared superior to total cholesterol or any of the apolipoprotein options. Guidelines should consider using non-HDL cholesterol or a ratio measure for initial treatment decisions and subsequent monitoring.

[1]  P. Glasziou,et al.  Criteria for monitoring tests were described: validity, responsiveness, detectability of long-term change, and practicality. , 2014, Journal of clinical epidemiology.

[2]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[3]  P. Glasziou,et al.  The rise of cholesterol testing: how much is unnecessary. , 2011, The British journal of general practice : the journal of the Royal College of General Practitioners.

[4]  P. Glasziou,et al.  Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data , 2011, BMJ : British Medical Journal.

[5]  Rafael Perera,et al.  Lipid re-screening: what is the best measure and interval? , 2009, Heart.

[6]  Stephane Heritier,et al.  Monitoring Cholesterol Levels: Measurement Error or True Change? , 2008, Annals of Internal Medicine.

[7]  P. Glasziou,et al.  Choosing the Best Monitoring Tests , 2008 .

[8]  J. Robson,et al.  Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease , 2007, Heart.

[9]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[10]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[11]  M. Pencina,et al.  Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. , 2007, JAMA.

[12]  W. Howard.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[13]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[14]  A. Tonkin,et al.  National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005. , 2005 .

[15]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[16]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[17]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[18]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[19]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[20]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[21]  A. Keech,et al.  Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? , 2002, Circulation.

[22]  J. Frohlich,et al.  Hypertriglyceridemic hyperapoB in type 2 diabetes. , 2002, Diabetes care.

[23]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[24]  Bruce Kinosian,et al.  Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios , 1994, Annals of Internal Medicine.

[25]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.